Range Low Price High Price Comment
30 days $0.0200 $0.120 Thursday, 28th Mar 2024 CALA stock ended at $0.0246. This is 22.75% more than the trading day before Wednesday, 27th Mar 2024. During the day the stock fluctuated 0% from a day low at $0.0246 to a day high of $0.0246.
90 days $0.0200 $0.120
52 weeks $0.0100 $0.500

Historical Calithera Biosciences prices

Date Open High Low Close Volume
2023-05-04 $0.0100 $0.0325 $0.0100 $0.0250 11 035
2023-05-03 $0.0250 $0.0325 $0.0250 $0.0250 17 942
2023-05-02 $0.0250 $0.0290 $0.0250 $0.0250 5 616
2023-05-01 $0.0150 $0.0369 $0.0150 $0.0250 28 041
2023-04-28 $0.0100 $0.0450 $0.0100 $0.0200 140 906
2023-04-27 $0.0400 $0.0520 $0.0400 $0.0400 23 730
2023-04-26 $0.0410 $0.0580 $0.0410 $0.0422 12 974
2023-04-25 $0.0400 $0.0580 $0.0400 $0.0400 5 869
2023-04-24 $0.0450 $0.0450 $0.0400 $0.0400 8 450
2023-04-21 $0.0400 $0.0400 $0.0400 $0.0400 1 376
2023-04-20 $0.0410 $0.0550 $0.0410 $0.0410 20 539
2023-04-19 $0.0400 $0.0569 $0.0400 $0.0410 567
2023-04-18 $0.0411 $0.0520 $0.0411 $0.0520 92 339
2023-04-17 $0.0411 $0.0700 $0.0411 $0.0422 2 866
2023-04-14 $0.0600 $0.0600 $0.0410 $0.0560 4 711
2023-04-13 $0.0400 $0.0560 $0.0400 $0.0560 1 748
2023-04-12 $0.0700 $0.0718 $0.0411 $0.0420 5 835
2023-04-11 $0.0400 $0.0770 $0.0400 $0.0460 8 910
2023-04-10 $0.0450 $0.0799 $0.0420 $0.0520 72 322
2023-04-06 $0.0450 $0.0500 $0.0450 $0.0500 514
2023-04-05 $0.0500 $0.0525 $0.0465 $0.0525 746
2023-04-04 $0.0580 $0.0600 $0.0425 $0.0470 7 719
2023-04-03 $0.0450 $0.103 $0.0410 $0.0590 57 859
2023-03-31 $0.0450 $0.0550 $0.0400 $0.0550 66 403
2023-03-30 $0.0550 $0.0550 $0.0401 $0.0401 25 619
Click to get the best stock tips daily for free!

About Calithera Biosciences

Calithera Biosciences Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas... CALA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT